Important Announcement!

Important announcement for Lynch Syndrome cancer patients! Until now the FDA approved cancer treatments based on where in your body the cancer originated, for example breast, lung, etc.  This is the FIRST time the FDA has approved a treatment based on a common biomarker in a tumor rather than the location in the body that the cancer originated. This is an important first for the cancer community.  The 2 biomarkers are MSI-H (high microsatellite instability) and dMMR (mismatch repair deficiency).  These biomarkers are the hallmarks of most Lynch Syndrome tumors. The immunotherapy drug pembrolizumab (Keytruda) is approved for adults and pediatric patients who have unresectable or metastatic solid tumors with one of these biomarkers.

Learn more:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm